Lanmi 4mg lesvi medicine prevents and treats asthma (4 blisters x 7 tablets)

Dosage form Box of 4 blisters x 7 tablets
Specifications Montelukast

Ingredient

Composition information	Content
Montelukast	4mg

Uses

indications

lanmi 4mg drug indicated in the following cases:

Laivmi 4mg chewing tablets are indicated in treating asthma as a supportive therapy for patients aged 2-5 with persistent mild to medium -level asthma that is not fully controlled by inhaled corticosteroids and in users of the Beta owner of the short -acting effect that does not control the clinically controlled asthma attacks as desired.

Laivmi 4mg chewing tablets can also be an alternative treatment option for low -dose inhaled corticosteroids for patients from 2-5 years old with mild persistent asthma without a history of severe severe asthma attacks need to use oral corticosteroids, and in people who cannot use inhaled corticosteroids.

Laivmi 4mg chewing tablet is also indicated in asthma prevention for patients from 2-5 years or older, of which the main cause is the bronchospasm of exertion.

Pharmacokology

Pharmacological group: Leukotriene receptor anti -receptor drugs. ATC code: RO3D CO3.

Montelukast is a selective antagonist on Leukotrien receptor. Montelukast is associated with Cysteinyl Totrien type 1 in the upper and lower respiratory tract to prevent the effects of asthma and allergic rhinitis caused by Leukotrien intermediate.

In asthma: The effect of Leukotrien intermediate substance includes a number of respiratory effects such as bronchospasm, mucus secretion, and permeability of blood vessels.

In allergic rhinitis: Cysteinyl Leukotrien is secreted from nasal mucus after exposure to allergens in early and late reactions and is associated with allergic rhinitis symptoms. The stimulating test in the nose with cysteinyl leukotrien shows that cysteinyl leukotrien increases the airway response in the nose and symptoms in the nose.

Pharmacokinetics

absorption

Montelukast is quickly absorbed after drinking. With 10 mg films, the average peak concentration in plasma (CMAX) is achieved after taking 3 hours (TMAX) in adults when hungry. The average oral bioavailability is 64%. Oral bioavailability and cmax are not affected by conventional food. The safety and effectiveness of the drug is proved in clinical trials when using a 10 mg film tablet does not care about the meal time. With 5 mg chewing tablets, CMAX is achieved after 2 hours of adults. The average oral bioavailability is 73% and reduced to 63% by conventional food.

Distribution

Montelukast binds more than 99% of plasma proteins. The volume of distribution in the stable state of Montelukast on average 8 - 11 liters. Mouse studies with Montelukast are radioactive, showing the minimum distribution that passes through the brain barrier. Moreover, the concentration of the substance is radioactive at 24 hours after drinking is the lowest of all other tissues.

Biological Change

Montelukast is widely metabolized. In studies with treatment doses, the plasma concentration of metabolites of Montelukast cannot be detected in a stable state in adults and children.

In vitro studies use human liver micro -codes that Cytochrom P450 3A4, 2A6 and 2C9 are associated with Montelukast metabolism. Based on the results of in vitro saves further on human liver micro -microscopic, Montelukast's treatment concentration in plasma does not inhibit the cytochrom P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to Montelukast's therapeutic effect is the lowest.

Elimination

Montelukast's clearance in plasma is 45 ml/min in healthy adults. After a dose of Montelukast oral radioactive, 86% of radioactive activity is found in the blisters for 5 days and Characteristics in patients: No need to adjust the dose for the elderly or mild liver failure to medium. Studies in patients with renal failure have been conducted. Because Montelukast and metabolites are excreted in biliary tract, do not need to adjust the dose for patients with renal impairment. There is no data on pharmacokinetics of Montelukast in patients with severe liver failure (Child-Pugh> 9). With high doses of Montelukast (20 times and 60 times higher than the recommended dose for adults), there has been a decrease in serum concentration of theophylin. Do not see this effect at 10 mg/time/day.

Before taking Lanmi 4mg lesvi medicine prevents and treats asthma (4 blisters x 7 tablets)

How to use

The lanmi 4mg chewing tablet can be chewed or swallowed. If swallowed, drink enough water (for example, a glass of water).

Dosage

This drug is used for children under the supervision of adults.

The dose for children from 2 to 5 years old is a chewing tablet of Lainmi 4mg daily in the evening. Laivmi 4mg chewing tablets should be used for 1 hour or 2 hours after meals. There is no need to adjust the dose for patients with this age. Do not use for children under 2 years old.

General recommendations: Montelukast's treatment effect on asthma control parameters achieved within 1 day.

Patients should be advised to continue treating Montkulast even when their asthma is being controlled as well as in the severe asthma stage.

No dose adjustment for patients with renal impairment, or mild to moderate liver failure. No data in patients with severe liver failure. The male and female patient is the same dose.

Laivmi 4mg chewing tablet is an alternative treatment option for low -dose inhaled corticosteroids for mild and occasional asthma in children: Montelukast is not recommended for alone in the treatment of persistent persistent asthma.

The use of Montelukast as an alternative treatment option for low -dose inhaled corticosteroids for children with mild and transient asthma should only be considered for patients without a history of severe severe asthma attacks that need oral corticosteroids and in those who are proven to be inhaled corticosteroids.

Mild persistent asthma is defined as asthma symptoms that occur more than once a week but less than 1 time/day, night symptoms occur more than 2 times per month but less than 1 time/week, normal lung function between asthma batches.

If the control of asthma attacks does not meet the desired (usually within 1 month), the need to use additional supportive therapy or another anti -inflammatory drug based on asthma treatment should be assessed.

Montelukast treatment is associated with other asthma treatments: When the treatment with Montelukast is used as a supportive therapy for inhaled corticosteroid therapy, not using Montelukast for sudden replacement for inhaled corticosteroids.

Montelukast is used for children from 2-5 years old, which mainly bronchospasm due to exertion.

In children from 2 to 5 years old, bronchospasm of exercise can be a major manifestation of persistent asthma that requires treatment with inhaled corticosteroids. Patients should be assessed after 2-4 weeks of treatment with Montelukast. If the satisfactory response is not achieved, an additional or different therapy needs to be considered.

Specific dose depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose?

Overdose:

There is no special information about Montelukast overdose treatment. In chronic asthma studies, Montelukast has been used at a dose of up to 200 mg/day for adults for 22 weeks and in short -term studies, up to 900 mg/day for patients for about 1 week without any serious abnormal phenomena.

There have been reports on the overdose during the time of the drug circulating in the market and in clinical studies to Montelukast.

These reports include reports in adults and children with a high doses of 1000 mg (approximately 61 mg/kg in children 42 months old). Signs in testing and clinically have been monitored in accordance with data on the safety of drugs in adults and children.

There are no unwanted phenomena in most overdose reports. The most common signs of disadvantages that occur in Montelukast's safety data and include abdominal pain, sleep, thirst, headache, vomiting and hyperactivity of mental mental movement.

Management: It is not known whether Monkelukast can be separated by the peritoneal or hemorrhage.

Actively monitor the soles of timely management.

In an emergency, call the 115 emergency center immediately or go to the nearest local health station.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

Montelukast has been evaluated in clinical studies in asthma patients as follows:

5 mg chewing tablets studied on about 1,750 patients from 6 to 14 years old.

4 mg chewing inflammation studies on about 851 children from 2 to 5 years old.

The following unwanted reactions related to the use of drugs in the common reports are commonly reported (≥1/100 to

The body of the body in the body Patients 15 years and older (2 studies 12 weeks; Sample size n = 795) Pediatric patients 6 - 14 years old (1 study 8 weeks; Sample size n = 201) (2 Studies 56 weeks; sample size n = 615) 56 weeks; n = 278) Abdominal change.

Experience in using drugs after circulation on the market: Refer to the information instruction sheet.

Notify the physician the unwanted effects when using the drug.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

Laivmi 4mg drug contraindicated in the following cases:

Hypersensitivity to active ingredients or any excipients of the drug.

Be cautious when using

Patients should be advised to never be used by Montelukast to treat acute asthma attacks and maintain appropriate medications for normal treatment for quick treatment purposes. If the acute asthma attacks occur, the inhaled beta -shaped owner should be used for short -acting beta. Patients should see a doctor if they need to use the inhaled beta -shorter -shorter than normal.

Montelukast should not suddenly replace oral or inhaled corticosteroids.

There is no data proving that oral corticosteroid dose can be reduced when used simultaneously with Montelukast.

In rare cases, patients taking asthma drugs including Montelukast may have eosin hypernagus, occasionally clinical manifestations of vasculitis associated with Churg-Strauss syndrome, a disease that is often treated with systemic corticosteroids. The possibility of Leukotrien receptor blockers may be associated with the appearance of Churg-Strauss syndrome that cannot be excluded nor determined. Doctors should be warned of eosin eosinophilia, blood vessel rash, obedient pulmonary symptoms, heart complications and/or neurological diseases occur in their patients. Patients with these symptoms should be considered and distributed their treatments should be evaluated.

Laivmi 4mg chewing tablets contain aspartam, derived from phenylalanin. Patients with phenylpyruvic acid should consider a lanmi chewing tablet containing phenylalanin in a quantity of the king and 1.35 mg of phenylalanin corresponding to each dose.

The effect of the drug on the ability to drive and operate machinery

unknown effects of the drug.

Use drugs for women during pregnancy and lactation

Pregnant women

Animal studies do not show harmful effects on pregnancy or the development of embryo/fetal. The data restrictions from existing pregnancy data, does not show the causal relationship between Montelukast and deformities (such as spending defects), this relationship is rare in the process of circulating drugs in the world. Laivmi 4mg chewing tablet can be used during pregnancy only when it is considered really necessary.

breastfeeding women

Used in nursing women: Mouse studies have shown that Montelukast is excreted in milk. It is not known whether Montelukast has excreted in human milk. Laivmi 4mg chewing tablet can be used for women who are breastfeeding whenever they are really necessary.

Drug interaction

Montelukast can be used with other therapies that are often used in preventive and chronic treatment of asthma. In drug interactions, clinical doses are recommended not to cause clinical important effects on the pharmacokinetics of the following drugs: Theophylin, Prednison, Prednisolon, Ethinyl Estradiol/Norethindron 35/1), Terfenadin, Digoxin and Warfarin.

The area under the plasma concentration curve (AUC) for Montelukast decreased by about 40% in patients using simultaneously with phenobarbital. Because Montelukast is metabolized by CYP 3A4, should be cautious, especially in children, when using Montelukast simultaneously with CYP 3A4 induction drugs, such as Phenytoin, Phenobarbital and Rifampicin.

Cavalry: Due to no studies on the correlation of the drug, do not mix this drug with other drugs.

Storage

Leave a cool place, avoid light, temperatures below 30⁰C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.